850350-09-3

Basic information

• Product Name: 2-BENZYLOXY-5-BROMO-BENZOIC ACID BENZYL ESTER
• Synonyms: 2-BENZYLOXY-5-BROMO-BENZOIC ACID BENZYL ESTER;benzyl 2-(benzyloxy)-5-bromobenzoate(WX191545)
• CAS NO: 850350-09-3
• Molecular Formula: C₂₁H₁₇BrO₃
• Molecular Weight: 397.26
• Mol File: 850350-09-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BENZYLOXY-5-BROMO-BENZOIC ACID BENZYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZYLOXY-5-BROMO-BENZOIC ACID BENZYL ESTER(850350-09-3)
• EPA Substance Registry System: 2-BENZYLOXY-5-BROMO-BENZOIC ACID BENZYL ESTER(850350-09-3)

Safety Data

• Hazardous Substances Data: 850350-09-3(Hazardous Substances Data)

Upstream product

• 89-55-4 5-bromosalicyclic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 1237518-03-4 benzyl 2-(benzyloxy)-5-(piperidin-1-yl)benzoate 
• 1285516-32-6 benzyl 2-(benzyloxy)-5-(4-methylpiperazin-1-yl)benzoate 
• 1237517-76-8 phenylmethyl 2-[(phenylmethyl)oxy]-5-(4-pyridinyl)benzoate 
• 1237518-04-5 2-hydroxy-5-(piperidin-1-yl)benzoic acid 
• 1237517-83-7 benzyl 2-(benzyloxy)-5-(pyrimidin-2-yl)benzoate 
• 1237518-05-6 2-acetoxy-5-(piperidin-1-yl)benzoic acid 
• 1237514-72-5 sodium 2-(2-hydroxy-5-(pyridin-4-yl)benzamido)-4-(2-methoxyphenyl)benzoic acid 

Relevant articles and documents

MALIC ENZYME INHIBITORS

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors

Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson's disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability.

NOVEL COMPOUNDS

The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.